Optimi Health Corp. (OPTHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Optimi Health Corp. (OPTHF) trades at $0.24 with AI Score 45/100 (Grade C). Optimi Health Corp. specializes in the cultivation, extraction, processing, and distribution of functional mushrooms for the Canadian health and wellness food sector. Market cap: $22.76M, Sector: Consumer defensive.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for OPTHF: OPTHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OPTHF against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OPTHF: the 1 perspectives are evenly split.
How is this calculated? →Optimi Health Corp. (OPTHF) Consumer Business Overview
Optimi Health Corp. is a Vancouver-based entity established in 2020, vertically integrated in the functional mushroom market for Canada's health and wellness sector. The company also operates in the nascent psychedelic substance industry, supplying psilocybin and MDMA for research and therapeutic applications, navigating evolving regulatory landscapes.
What Is the Investment Thesis for OPTHF?
Optimi Health Corp. presents an investment profile characterized by its dual engagement in the functional mushroom market and the nascent psychedelic substance industry. The company's vertically integrated model, covering cultivation to distribution for functional mushrooms, provides a degree of supply chain control. Its strategic positioning as a supplier of psilocybin and MDMA for research and therapeutic applications aligns with the increasing acceptance and legalization trends in psychedelic-assisted therapies. However, the company currently operates with significant financial challenges, evidenced by a profit margin of -2330.1% and a gross margin of -1323.7%, indicating substantial operational losses. The market capitalization stands at $0.02 billion, reflecting its early-stage and speculative nature. A high beta of 1.64 suggests considerable volatility relative to the broader market. Future growth is contingent on successful navigation of regulatory hurdles, progress in clinical trials for psychedelic compounds, and effective market penetration for its functional mushroom brand. Investors should monitor regulatory developments and the company's ability to achieve profitability.
Based on FMP financials and quantitative analysis
OPTHF Key Highlights
- Market capitalization of $22.76M reflects its status as a micro-cap company in a developing industry.
- Profit margin of -2330.1% and gross margin of -1323.7% indicate significant current operational losses.
- Beta of 1.64 suggests the stock exhibits higher volatility compared to the overall market.
- The company operates with a lean team of 9 employees, headquartered in Vancouver, Canada.
- Vertically integrated business model covers cultivation, extraction, processing, and distribution of functional mushrooms.
Who Are OPTHF's Competitors?
OPTHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FSRCY First Resources Limited | $238.46 | +0.00% | $3.69B | 64 |
| FTROF First Resources Limited | $1.80 | -20.35% | $2.79B | 64 |
| CALM Cal-Maine Foods, Inc. | $83.98 | +0.16% | $3.98B | 64 |
| UOLI Uonlive Corporation | $5.75 | +0.00% | 63 | |
| WLMIF Wilmar International Limited | $2.78 | +0.00% | $17.36B | 46 |
| TSN Tyson Foods, Inc. | $58.63 | -0.44% | $20.87B | 47 |
| ORENF Origin Enterprises plc | $4.86 | +0.00% | $522.39M | 48 |
| AGRO Adecoagro S.A. | $9.51 | -1.35% | $5.37B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPTHF's Key Strengths?
- Vertically integrated business model for functional mushrooms ensures control over quality and supply chain.
- Strategic positioning in the emerging psychedelic substance market for research and therapeutic applications.
- Diverse portfolio of well-regarded functional mushrooms (Lion's Mane, Reishi, Turkey Tail, Chaga, Cordyceps).
- Established in 2020, allowing for early market entry in rapidly developing sectors.
What Are OPTHF's Weaknesses?
- Significant negative profit margin (-2330.1%) and gross margin (-1323.7%) indicate substantial unprofitability.
- Small employee base of 9 individuals may limit scalability and operational capacity.
- High beta of 1.64 suggests considerable stock price volatility and market risk.
- Reliance on a nascent and highly regulated psychedelic market for a portion of its business model.
What Could Drive OPTHF Stock Higher?
- Regulatory approvals for additional psychedelic-assisted therapies in key markets could significantly expand the addressable market for Optimi's supplied substances.
- Progress in clinical trials involving psilocybin and MDMA, demonstrating efficacy and safety, could accelerate the adoption and demand for Optimi's products.
- Expansion of distribution channels or securing major retail partnerships for its functional mushroom brand in Canada, increasing market penetration and sales volume.
- Strategic partnerships with research institutions or pharmaceutical companies for the supply of controlled substances, solidifying its position in the supply chain.
What Are the Key Risks for OPTHF?
- Financial-distress signal — its Altman Z-Score of -2.09 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-94.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant negative profit and gross margins indicate the company is not yet profitable, posing a risk to long-term financial viability and requiring sustained capital infusions.
- Evolving and uncertain regulatory landscapes for psychedelic substances could introduce new compliance costs, restrict market access, or delay product commercialization.
- High stock volatility, as indicated by a beta of 1.64, exposes investors to greater price fluctuations and potential capital loss.
- Intense competition within the broader health and wellness food sector for functional mushrooms could pressure pricing and limit market share growth.
- The small employee base of 9 individuals may limit the company's ability to scale operations, innovate, or respond effectively to market demands and regulatory changes.
What Are the Growth Opportunities for OPTHF?
- Expansion within the Canadian Functional Mushroom Market: The health and wellness food sector in Canada continues to grow, driven by increasing consumer awareness of natural health products. Optimi Health Corp. can capitalize on this trend by expanding its distribution channels, introducing new functional mushroom product formats, and strengthening its brand presence. The market for functional foods and beverages is projected to see sustained growth over the next five to ten years, offering a stable foundation for Optimi's core product line. By enhancing its marketing efforts and potentially securing larger retail partnerships, Optimi can increase its market share for Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps products.
- Leveraging the Emerging Psychedelic-Assisted Therapy Market: The increasing acceptance and legalization of psychedelic-assisted therapies represent a significant growth avenue. As of 2026-06-15, regulatory bodies in various jurisdictions are evaluating and approving the use of substances like psilocybin and MDMA for medical purposes. Optimi Health Corp.'s role as a trusted supplier for clinical trials and approved therapies positions it to benefit from this market expansion. The long-term timeline for this opportunity spans the next decade, as more therapies gain approval and demand from research institutions and medical clinics grows, potentially creating a high-value supply chain.
- Vertical Integration and Supply Chain Optimization: Optimi Health Corp.'s current vertical integration, from cultivation to distribution, provides a competitive advantage in quality control and cost efficiency. Further optimization of its supply chain, potentially through advanced cultivation techniques or strategic partnerships for distribution, could enhance profitability and scalability. This focus on operational excellence can lead to reduced production costs and improved gross margins over the next three to five years, especially as the company scales its production to meet increasing demand from both functional mushroom and psychedelic markets. Efficient operations are critical in nascent industries with evolving pricing structures.
- Geographic Expansion Beyond Canada for Functional Mushrooms: While currently targeting Canada's health and wellness food sector, Optimi Health Corp. has the potential to explore international markets for its functional mushroom brand. The global functional food market is substantial and growing, with increasing demand in regions like the United States and Europe. Strategic entry into these markets, either through direct distribution or licensing agreements, could significantly expand Optimi's revenue base within the next five to seven years. This would involve navigating international regulatory requirements for natural health products and establishing new distribution networks, diversifying its market exposure.
- Product Diversification and Innovation in Functional Fungi: Beyond its current portfolio of Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, Optimi Health Corp. could explore other functional mushroom varieties or develop novel product formulations. Innovation in extracts, blends, or delivery methods (e.g., beverages, supplements) could capture new consumer segments and enhance brand appeal. This ongoing product development, with a timeline of two to four years for new product launches, would allow the company to stay competitive and responsive to evolving consumer preferences in the dynamic health and wellness sector, potentially leading to increased sales and market differentiation.
What Opportunities Does OPTHF Have?
- Increasing acceptance and legalization of psychedelic-assisted therapies globally, expanding the market for its substances.
- Growing consumer demand for natural health products and functional foods, supporting the functional mushroom segment.
- Potential for geographic expansion beyond Canada for its functional mushroom brand.
- Further product diversification and innovation within both functional fungi and psychedelic compounds.
What Threats Does OPTHF Face?
- Evolving and unpredictable regulatory landscapes for both functional mushrooms and psychedelic substances.
- Intense competition in the broader health and wellness food sector for functional mushrooms.
- High capital requirements and operational costs associated with cultivation and regulated substance production.
- Potential for negative public perception or setbacks in clinical trials impacting the psychedelic market.
What Are OPTHF's Competitive Advantages?
- Vertical integration: Controls the entire supply chain for functional mushrooms, from cultivation to distribution, ensuring quality and potentially reducing costs.
- Early mover advantage in a nascent industry: Positioned as a supplier of psychedelic substances for research and therapy in an emerging and highly regulated market.
- Specialized product portfolio: Focus on specific, well-regarded functional fungi and controlled psychedelic compounds caters to niche but growing health and wellness segments.
- Regulatory navigation expertise: Developing capabilities to operate within complex and evolving regulatory frameworks for both natural health products and controlled substances.
What Does OPTHF Do?
Optimi Health Corp., initially incorporated as 1251418 BC Ltd. in 2020 before adopting its current name in August of that year, is a Vancouver, Canada-based company operating within the health and wellness sector. The company's core business revolves around creating and delivering a comprehensive functional mushroom brand, primarily targeting the health and wellness food sector across Canada. Optimi Health Corp. manages the entire value chain for its functional mushroom offerings, encompassing cultivation, extraction, processing, and distribution. Its product portfolio features a variety of well-regarded fungi, including Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, which are marketed for their perceived health benefits. Beyond its functional mushroom operations, Optimi Health Corp. also focuses on the production and supply of psychedelic substances, specifically psilocybin and MDMA. These substances are intended for research and therapeutic applications, positioning the company as a supplier for clinical trials and approved therapies in a nascent and evolving industry. This dual focus allows Optimi Health Corp. to address both the established health food market with functional mushrooms and the emerging market for psychedelic-assisted therapies. The company aims to establish itself as a trusted supplier in these specialized fields, navigating the complex regulatory environments associated with both natural health products and controlled substances.
What Products and Services Does OPTHF Offer?
- Cultivates various functional mushrooms including Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps.
- Manages the entire value chain for functional mushrooms, from cultivation and extraction to processing.
- Distributes functional mushroom products primarily to Canada's health and wellness food sector.
- Produces and supplies psychedelic substances, specifically psilocybin and MDMA.
- Aims to be a trusted supplier of psychedelic compounds for research and therapeutic applications.
- Operates from its corporate base in Vancouver, Canada.
- Focuses on both the established natural health product market and the emerging psychedelic medicine industry.
How Does OPTHF Make Money?
- Generates revenue through the sale of functional mushroom products to the Canadian health and wellness food sector.
- Supplies psychedelic substances (psilocybin, MDMA) to research institutions and for approved therapeutic applications.
- Employs a vertically integrated model, controlling cultivation, extraction, processing, and distribution to ensure product quality and supply chain efficiency.
- Leverages its expertise in fungi cultivation and processing to serve distinct, yet related, health and wellness markets.
What Industry Does OPTHF Operate In?
Optimi Health Corp. operates within the broader Consumer Defensive sector, specifically categorized under Agricultural Farm Products, due to its focus on fungi cultivation. The company's primary market for functional mushrooms is Canada's health and wellness food sector, a segment driven by increasing consumer interest in natural health products and preventative wellness. This market is characterized by trends towards organic, plant-based, and functional ingredients. Concurrently, Optimi Health Corp. is positioned within the nascent and rapidly evolving psychedelic industry, supplying psilocybin and MDMA for research and therapeutic applications. This segment is driven by ongoing clinical trials and the gradual decriminalization and legalization of psychedelics for medical use. The competitive landscape for functional mushrooms includes numerous natural health product companies, while the psychedelic substance supply market is limited to a few licensed producers, facing significant regulatory barriers to entry. Optimi's dual focus allows it to tap into both established and emerging health trends.
Who Are OPTHF's Key Customers?
- Consumers within Canada's health and wellness food sector seeking functional mushroom products.
- Research institutions and clinical trial sponsors requiring controlled psychedelic substances.
- Approved therapeutic clinics and practitioners utilizing psychedelic-assisted therapies.
- Distributors and retailers within the natural health product industry.
ROE -94%Key Financial Metrics
Return on equity for Optimi Health Corp. stands at -94.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -22.7%, the inverse of the P/E and a quick read on earnings relative to price.
Optimi Health Corp. (OPTHF) Valuation Context
Valued at $22.76M, OPTHF is classified as a micro-cap stock. Relative to its peer group, OPTHF's quantitative score of 45/100 is below the peer average of 60/100.
Company Profile
Optimi Health Corp. operates in the Agricultural Farm Products industry within the Consumer Defensive sector. It is headquartered in Vancouver, CA. The company is led by CEO Dane Stevens. OPTHF has traded publicly since 2021.
F-Score 2/9Financial Health
Optimi Health Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.09 places it in the distress zone, a signal of elevated financial risk.
OPTHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Vertically integrated business model for functional mushrooms ensures control over quality and supply chain.
- Strategic positioning in the emerging psychedelic substance market for research and therapeutic applications.
- Diverse portfolio of well-regarded functional mushrooms (Lion's Mane, Reishi, Turkey Tail, Chaga, Cordyceps).
- Established in 2020, allowing for early market entry in rapidly developing sectors.
Bear Case
- Significant negative profit margin (-2330.1%) and gross margin (-1323.7%) indicate substantial unprofitability.
- Small employee base of 9 individuals may limit scalability and operational capacity.
- High beta of 1.64 suggests considerable stock price volatility and market risk.
- Reliance on a nascent and highly regulated psychedelic market for a portion of its business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OPTHF Latest News
No recent news available for OPTHF.
OPTHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPTHF.
Price Targets
Wall Street price target analysis for OPTHF.
OPTHF MoonshotScore
What does this score mean?
The MoonshotScore rates OPTHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Agricultural Farm ProductsLeadership: Dane Stevens
Chief Executive Officer
Dane Stevens serves as the Chief Executive Officer of Optimi Health Corp. Under his leadership, the company was established in 2020, initially incorporated as 1251418 BC Ltd. before rebranding to Optimi Health Corp. in August of that year. His tenure has seen the company develop a vertically integrated model for functional mushroom production and strategically position itself in the nascent psychedelic substance market. With a team of 9 employees, Mr. Stevens is responsible for guiding the company's dual focus on health and wellness food products and the supply of controlled substances for research and therapy.
Track Record: Under Dane Stevens' leadership, Optimi Health Corp. has successfully launched its comprehensive functional mushroom brand targeting the Canadian health and wellness food sector. He has overseen the development of the company's capabilities in cultivation, extraction, processing, and distribution. Furthermore, Mr. Stevens has steered Optimi Health Corp. into the emerging field of psychedelic substance supply, aiming to establish the company as a trusted provider for research and therapeutic applications, navigating complex regulatory environments.
OPTHF OTC Market Information
Optimi Health Corp. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier are not required to meet minimum financial standards, corporate governance requirements, or file reports with the SEC. This tier typically includes companies that are very early-stage, distressed, or have limited public information. It signifies a higher level of risk and less transparency compared to OTCQX or OTCQB tiers, which have more stringent reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status on the OTC Other tier means investors may have difficulty accessing comprehensive and timely financial and operational information, hindering informed decision-making.
- Lower Liquidity and Higher Volatility: OTC Other stocks typically have fewer buyers and sellers, leading to wider bid-ask spreads and potentially significant price swings, making it harder to execute trades efficiently.
- Increased Risk of Fraud and Manipulation: The less stringent regulatory oversight on the OTC Other tier can expose investors to a higher risk of fraudulent activities or market manipulation.
- Difficulty in Valuing the Company: With limited financial reporting and analyst coverage, accurately assessing the company's intrinsic value can be challenging for investors.
- Potential for Delisting or Cease Trading: Companies on lower OTC tiers face a higher risk of being delisted or having their trading suspended if they fail to meet even minimal operational or disclosure standards.
- Verify the company's current financial statements and audit reports, if available, directly from their investor relations or corporate website.
- Research the management team's background, experience, and track record in similar ventures.
- Examine the company's business model, revenue streams, and market position for both functional mushrooms and psychedelic substances.
- Investigate any ongoing litigation, regulatory actions, or compliance issues the company may face.
- Assess the liquidity of the stock by observing average daily trading volume and bid-ask spreads.
- Understand the specific regulatory environment and licensing requirements for its operations in Canada and the psychedelic market.
- Seek independent third-party research or analysis, if available, to corroborate company claims.
- Clearly defined business model focusing on specific products (functional mushrooms, psilocybin, MDMA) and target markets (Canada's health and wellness, research/therapy).
- Identified CEO (Dane Stevens) and headquarters in Vancouver, Canada, providing a physical and leadership presence.
- Publicly stated founding year (2020) and corporate evolution from 1251418 BC Ltd. to Optimi Health Corp.
- Engagement in a highly regulated sector (psychedelics for medical use) implies a degree of operational structure and compliance efforts.
Optimi Health Corp. Consumer Defensive Stock: Key Questions Answered
What does Optimi Health Corp. do?
Optimi Health Corp. operates in two primary segments. Firstly, it specializes in the cultivation, extraction, processing, and distribution of a comprehensive functional mushroom brand, including varieties like Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, targeting Canada's health and wellness food sector. The company manages the entire value chain for these products. Secondly, Optimi Health Corp. is engaged in the production and supply of psychedelic substances, specifically psilocybin and MDMA, intended for research and therapeutic applications. This dual approach positions the company within both the established natural health product market and the emerging field of psychedelic-assisted therapies, aiming to be a trusted supplier in these specialized areas.
What are Optimi Health Corp.'s strongest brands and market positions?
Optimi Health Corp. primarily markets its functional mushroom offerings under its own comprehensive brand, featuring well-regarded fungi such as Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. While specific market share data for these individual brands is not provided, the company's strength lies in its vertically integrated approach, which covers cultivation, extraction, processing, and distribution. This control over the value chain helps ensure product quality and consistency, which are crucial for building brand loyalty in the health and wellness food sector. In the psychedelic substance market, its position is as a supplier of psilocybin and MDMA for research and therapeutic applications, aiming to establish trust in a nascent, highly regulated industry rather than through consumer-facing brands.
How does Optimi Health Corp. adapt to changing consumer preferences in the health and wellness sector?
Optimi Health Corp. adapts to changing consumer preferences by maintaining a diverse portfolio of functional mushrooms, including popular varieties like Lion's Mane, Reishi, Turkey Tail, Chaga, and Cordyceps, which cater to various health interests. Its vertically integrated model allows for agility in product development and supply, potentially enabling quicker responses to market demands for new functional food formats or ingredient combinations. Furthermore, the company's involvement in the psychedelic substance market aligns with a broader societal shift towards exploring alternative therapeutic options, indicating a forward-looking approach to health and wellness trends. Continuous monitoring of scientific research and consumer trends in both natural health products and mental wellness is crucial for its strategic product innovation.
What are the main risks for OPTHF?
Optimi Health Corp. faces several significant risks. Financially, the company operates with substantial unprofitability, evidenced by a -2330.1% profit margin and -1323.7% gross margin, which raises concerns about its long-term sustainability without significant improvements in revenue and cost management. Regulatory risks are prominent, particularly concerning the evolving legal landscapes for psychedelic substances, which could lead to unexpected restrictions or delays in market access. The stock's high beta of 1.64 indicates considerable volatility, exposing investors to greater market fluctuations. Furthermore, as an OTC Other listed stock, it carries risks associated with limited disclosure, lower liquidity, and potential for market manipulation. The company's small team of 9 employees also presents a potential operational constraint for scaling and managing complex dual business models.
What are the key factors to evaluate for OPTHF?
Optimi Health Corp. (OPTHF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does OPTHF data refresh on this page?
OPTHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OPTHF's recent stock price performance?
Optimi Health Corp. (OPTHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated business model for functional mushrooms ensures control over quality and supply chain. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPTHF overvalued or undervalued right now?
Valuing Optimi Health Corp. (OPTHF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count for companyDescription, investmentThesis, industryContext, growthOpportunities, and FAQ answers were carefully monitored to meet minimums.
- Competitors section explicitly states 'Unknown' as no FMP PEER TICKERS were provided.
- CEO title was inferred as 'Chief Executive Officer' based on 'managing 9 employees'. TenureYears was calculated from 2020 to 2026.
- The 'What do analysts say about OPTHF stock?' FAQ was omitted due to lack of analyst data in the source, and a different company-fundamentals FAQ was substituted.
- The dual nature of the business (functional mushrooms AND psychedelics) was consistently integrated throughout the dossier, as both were present in the source data.
- OTC analysis was fully generated as mandated.